459 related articles for article (PubMed ID: 21247385)
1. SCF E3 ubiquitin ligases as anticancer targets.
Jia L; Sun Y
Curr Cancer Drug Targets; 2011 Mar; 11(3):347-56. PubMed ID: 21247385
[TBL] [Abstract][Full Text] [Related]
2. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
[TBL] [Abstract][Full Text] [Related]
3. Cullin-RING Ligases as attractive anti-cancer targets.
Zhao Y; Sun Y
Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases.
Zhou W; Wei W; Sun Y
Cell Res; 2013 May; 23(5):599-619. PubMed ID: 23528706
[TBL] [Abstract][Full Text] [Related]
5. Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The Role in Cancer and as Cancer Targets.
Wei D; Sun Y
Genes Cancer; 2010 Jul; 1(7):700-7. PubMed ID: 21103004
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.
Zhao Y; Sun Y
Neoplasia; 2012 May; 14(5):360-7. PubMed ID: 22745582
[TBL] [Abstract][Full Text] [Related]
7. SCF
Cai L; Liu L; Li L; Jia L
Cell Signal; 2020 Jan; 65():109440. PubMed ID: 31678254
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy.
Tanaka T; Nakatani T; Kamitani T
Mol Oncol; 2012 Jun; 6(3):267-75. PubMed ID: 22306028
[TBL] [Abstract][Full Text] [Related]
9. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
Jia L; Li H; Sun Y
Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Luo Z; Pan Y; Jeong LS; Liu J; Jia L
Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
[TBL] [Abstract][Full Text] [Related]
11. SCF ubiquitin ligase-targeted therapies.
Skaar JR; Pagan JK; Pagano M
Nat Rev Drug Discov; 2014 Dec; 13(12):889-903. PubMed ID: 25394868
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.
Gorelik M; Orlicky S; Sartori MA; Tang X; Marcon E; Kurinov I; Greenblatt JF; Tyers M; Moffat J; Sicheri F; Sidhu SS
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3527-32. PubMed ID: 26976582
[TBL] [Abstract][Full Text] [Related]
13. Targeting E3 ubiquitin ligases for cancer therapy.
Sun Y
Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
[TBL] [Abstract][Full Text] [Related]
14. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.
Zhao Y; Morgan MA; Sun Y
Antioxid Redox Signal; 2014 Dec; 21(17):2383-400. PubMed ID: 24410571
[TBL] [Abstract][Full Text] [Related]
15. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
Yu Q; Xiong X; Sun Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
[TBL] [Abstract][Full Text] [Related]
16. An engineered platform for reconstituting functional multisubunit SCF E3 ligase in vitro.
Liu H; Liu S; Yu H; Huang X; Wang Y; Jiang L; Meng X; Liu G; Chen M; Jing Y; Yu F; Wang B; Li J
Mol Plant; 2022 Aug; 15(8):1285-1299. PubMed ID: 35751381
[TBL] [Abstract][Full Text] [Related]
17. Targeting SCF E3 Ligases for Cancer Therapies.
Liu J; Peng Y; Zhang J; Long J; Liu J; Wei W
Adv Exp Med Biol; 2020; 1217():123-146. PubMed ID: 31898226
[TBL] [Abstract][Full Text] [Related]
18. The role of SCF ubiquitin-ligase complex at the beginning of life.
Xie J; Jin Y; Wang G
Reprod Biol Endocrinol; 2019 Nov; 17(1):101. PubMed ID: 31779633
[TBL] [Abstract][Full Text] [Related]
19. Histone acetyltransferase CBP promotes function of SCF FBXL19 ubiquitin E3 ligase by acetylation and stabilization of its F-box protein subunit.
Wei J; Dong S; Yao K; Martinez MFYM; Fleisher PR; Zhao Y; Ma H; Zhao J
FASEB J; 2018 Aug; 32(8):4284-4292. PubMed ID: 29522376
[TBL] [Abstract][Full Text] [Related]
20. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
